Scientists uncover the ovarian cancer cause behind drug resistance and immune therapy failure - here's what the latest 2026 ...

Circulating tumor DNA (ctDNA) monitoring in participants (pts) with ovarian cancer treated with neoadjuvant pembrolizumab (pembro) + chemotherapy (chemo) ± anti–immunoglobulin-like transcript 4 (ILT4) ...

HIPEC addition to SCS did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer patients. Both SCS alone and SCS with HIPEC groups exhibited similar safety profiles, ...

The experimental drug mocertatug rezetecan (Mo‑Rez) is showing real promise in early clinical trials for ovarian and endometrial cancers that have returned after initial treatment (recurrent), enough ...

Keytruda with paclitaxel, with or without Avastin, improved PFS and OS in PRROC patients, irrespective of PD-L1 status. The trial showed significant benefits in both CPS ≥1 and intention-to-treat ...

SCS combined with HIPEC may improve overall survival in PSROC patients compared to SCS alone, with a statistically significant benefit observed. The risk of severe complications, including anemia and ...

A study led by Roswell Park Comprehensive Cancer Center provides new insight into the complex interactions of the "tumor-immune-gut axis," and its role in influencing immunotherapy responses in ...

Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: A systematic review and meta-analysis of randomized controlled trials. Impact of body mass ...

TORL BioTherapeutics LLC (TORL), a clinical stage oncology-focused biotechnology company, today announced preliminary Phase 1 safety and efficacy data of ixotatug vedotin (Ixo-V or TORL-1-23) in ...

KEYTRUDA® (pembrolizumab) plus chemotherapy (paclitaxel) with or without bevacizumab is the first immune checkpoint inhibitor-based regimen to show a statistically significant improvement in OS for ...

Patients with recurrent platinum-sensitive ovarian cancer did just as well with cytoreductive surgery alone as they did with surgery plus intraperitoneal chemotherapy, according to a randomized trial.

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. Approval stipulates use of the combination, with or without ...